高水平论文推送1——肿瘤学
各单位、部门，全体科研人员：
为促进学术交流与知识共享，助力科研人员及时了解各领域前沿动态与最新研究成果，现决定定期推送澳门金沙城中心_澳门十大电子游戏app下载-【首页】@学者发表的高水平论文。每篇推送将包含论文题目、作者信息、发表期刊/会议、核心观点摘要、研究亮点及创新点等关键内容。
本期主题为肿瘤学，希望为相关研究者的学术研究提供有益参考，提升学术水平。请有关单位、部门加强学校高水平论文的推介工作。
科学技术部
2025年8月1日
RNA sequencing: new technologies and applications in cancer research
RNA 测序：癌症研究中的新技术与应用
Issue JOURNAL OF HEMATOLOGY & ONCOLOGY 2020, Volume 13 Issue 1
期刊：《血液学与肿瘤学杂志》2020年，第13卷第1期
Author Hong Mingye / Tao Shuang / Zhang Ling / Diao Li-Ting / Huang Xuanmei / Huang Shaohui / Xie Shu-Juan / Xiao Zhen-Dong / Zhang Hua
Keywords RNA sequencing / Application / Cancer
Abstract
Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing to single-molecular, single-cell and spatial transcriptome approaches has enabled increasingly accurate, individual cell resolution incorporated with spatial information. Cancer, a major malignant and heterogeneous lethal disease, remains an enormous challenge in medical research and clinical treatment. As a vital tool, RNA sequencing has been utilized in many aspects of cancer research and therapy, including biomarker discovery and characterization of cancer heterogeneity and evolution, drug resistance, cancer immune microenvironment and immunotherapy, cancer neoantigens and so on. In this review, the latest studies on RNA sequencing technology and their applications in cancer are summarized, and future challenges and opportunities for RNA sequencing technology in cancer applications are discussed.
Cite this article as: [1]Hong Mingye, Tao Shuang, Zhang Ling, et al.RNA sequencing: new technologies and applications in cancer research[J].JOURNAL OF HEMATOLOGY & ONCOLOGY,2020,13(1).
信迪利单抗联合培美曲塞与铂类药物作为局部晚期或转移性非鳞状非小细胞肺癌一线治疗方案的疗效与安全性：一项随机、双盲、Ⅲ期研究（InnovENT抗PD-1-11肿瘤项目）
Issue JOURNAL OF THORACIC ONCOLOGY 2020, Volume 15 Issue 10 1636-1646
期刊：《胸部肿瘤学杂志》2020年，第15卷第10期，第1636-1646页
Author Yang Yunpeng / Wang Zhehai / Fang Jian / Yu Qitao / Han Baohui / Cang Shundong / Chen Gongyan / Mei Xiaodong / Yang Zhixiong / Ma Rui / Bi Minghong / Ren Xiubao / Zhou Jianying / Li Baolan / Song Yong / Feng Jifeng / Li Juan / He Zhiyong / Zhou Rui / Li Weimin / Lu You / Wang Yingyi / Wang Lijun / Yang Nong / Zhang Yan / Yu Zhuang / Zhao Yanqiu / Xie Conghua / Cheng Ying / Zhou Hui / Wang Shuyan / Zhu Donglei / Zhang Wen / Zhang Li
Keywords Nonsquamous NSCLC / Sintilimab / Pemetrexed / Platinum / Phase III study
Abstract
Introduction: Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the efficacy and safety of sintilimab with placebo, both in combination with such chemotherapy (ClinicalTrials.gov: NCTO 3607539). Methods: A total of 397 patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC without sensitizing EGFR or anaplastic lymphoma kinase genomic aberration were randomized (2:1 ratio) to receive either sintilimab 200 mg or placebo plus pemetrexed and platinum once every 3 weeks for four cycles, followed by sintilimab or placebo plus pemetrexed therapy. Crossover or treatment beyond disease progression was allowed. The primary end point was progression-free survival (PFS) as judged by an independent radiographic review committee. Results: As of November 15, 2019, the median follow-up was 8.9 months. The median PFS was significantly longer in the sintilimab-combination group than that in the placebo-combination group (8.9 versus 5.0 mo; hazard ratio, 0.482, 95% confidence interval [CI]: 0.362-0.643; p < 0.00001). The confirmed objective response rate was 51.9% (95% CI: 45.7%-58.0%) in the sintilimab-combination group and 29.8% (95% CI: 22.1%-38.4%) in placebo-combination group. The incidence of grade 3 or higher adverse events was 61.7% in sintilimab-combination group and 58.8% in placebo-combination group. Conclusions: In Chinese patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to chemotherapy with pemetrexed and platinum resulted in considerably longer PFS than with chemotherapy alone with manageable safety profiles. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
Cite this article as: [1]Yang Yunpeng, Wang Zhehai, Fang Jian, et al.Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)[J].JOURNAL OF THORACIC ONCOLOGY,2020,15(10):1636-1646.
信迪利单抗联合铂类药物与吉西他滨作为晚期或转移性鳞状非小细胞肺癌一线治疗方案的疗效：一项随机、双盲、Ⅲ期试验（ORIENT-12研究）结果
Issue JOURNAL OF THORACIC ONCOLOGY 2021, Volume 16 Issue 9 1501-1511
期刊：《胸部肿瘤学杂志》2021年，第16卷第9期，第1501-1511页
Author Zhou Caicun / Wu Lin / Fan Yun / Wang Zhehai / Liu Lianke / Chen Gongyan / Zhang Li / Huang Dingzhi / Cang Shundong / Yang Zhixiong / Zhou Jianying / Zhou Chengzhi / Li Baolan / Li Juan / Fan Min / Cui Jiuwei / Li Yuping / Zhao Hui / Fang Jian / Xue Jianxin / Hu Chengping / Sun Ping / Du Yingying / Zhou Hui / Wang Shuyan / Zhang Wen
Keywords Sintilimab / Squamous NSCLC / Platinum and gemcitabine / Combination / First-line
Abstract
Introduction: The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti-programmed cell death protein 1 antibody, plus platinum and gemcitabine (GP) has revealed encouraging efficacy as first-line therapy for sqNSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP. Methods: ORIENT-12, a randomized, double-blind, phase 3 study, was conducted at 42 centers in the People's Republic of China (ClinicalTrials.gov, number NCT03629925). Patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements were enrolled in the study. The stratification factors included clinical stage, choice of platinum, and programmed death-ligand 1 tumor proportion score. The patients, investigators, research staff, and sponsor team were masked to treatment assignment. Eligible patients were randomized 1:1, using an integrated web-response system, to receive sintilimab 200 mg or placebo plus GP every 3 weeks for four or six cycles, followed by sintilimab or placebo as maintenance therapy until disease progression or 2 years. The primary end point was progression-free survival (PFS), assessed by an independent radiographic review committee. Results: Between September 25, 2018 and July 26, 2019, a total of 543 patients were screened, of whom 357 patients were randomized to the sintilimab-GP group (n = 179) and the placebo-GP group (n = 178). After a median follow-up period of 12.9 months, sintilimab-GP continued to reveal a meaningful improvement in PFS than placebo-GP (hazard ratio = 0.536 [95% confidence interval: 0.422-0.681], p < 0.00001). Treatment-emergent adverse events of grade 3 or worse occurred in 86.6% patients in the sintilimab-GP group and in 83.1% in the placebo-GP group. The incidence of treatment-emergent adverse event leading to death was 4.5% and 6.7% in the two treatment groups, respectively. Conclusions: Regarding PFS, sintilimab plus GP reveals clinical benefit than GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC. The toxicity was acceptable, and no new unexpected safety signals were observed. (c) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Cite this article as: [1]Zhou Caicun, Wu Lin, Fan Yun, et al.Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)[J].JOURNAL OF THORACIC ONCOLOGY,2021,16(9):1501-1511.
Global variations in lung cancer incidence by histological subtype in 2020: a population-based study
2020年全球肺癌组织学亚型发病率差异：一项基于人群的研究
Issue LANCET ONCOLOGY 2023, Volume 24 Issue 11 1206-1218
期刊：《柳叶刀?肿瘤学》2023年，第24卷第11期，第1206-1218页
Author Zhang Yanting / Vaccarella Salvatore / Morgan Eileen / Li Mengmeng / Etxeberria Jaione / Chokunonga Eric / Manraj Shyam Shunker / Kamate Bakarou / Omonisi Abidemi / Bray Freddie
Keywords
Abstract
Background Lung cancer is the second most common cancer worldwide, yet the distribution by histological subtype remains unknown. We aimed to quantify the global, regional, and national burden of lung cancer incidence for the four main subtypes in 185 countries and territories.Methods In this population-based study, we used data from Cancer Incidence in Five Continents Volume XI and the African Cancer Registry Network to assess the proportions of adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma among all lung cancers by country, sex, and age group and subsequently applied these data to corresponding national (GLOBOCAN) estimates of lung cancer incidence in 2020. Unspecified morphologies were reallocated to specified subtypes. Age-standardised incidence rates were calculated using the world standard population to compare subtype risks worldwide, adjusted for differences in age composition between populations by country. Findings In 2020, there were an estimated 2 206 771 new cases of lung cancer, with 1 435 943 in males and 770 828 in females worldwide. In males, 560 108 (39%) of all lung cancer cases were adenocarcinoma, 351 807 (25%) were squamous cell carcinoma, 163 862 (11%) were small-cell carcinoma, and 115 322 (8%) were large-cell carcinoma cases. In females, 440 510 (57%) of all lung cancer cases were adenocarcinoma, 91 070 (12%) were squamous cell carcinoma, 68 224 (9%) were small-cell carcinoma, and 49 246 (6%) were large-cell carcinoma cases. Age-standardised incidence rates for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, were estimated to be 12 center dot 4, 7 center dot 7, 3 center dot 6, and 2 center dot 6 per 100 000 person-years in males and 8 center dot 3, 1 center dot 6, 1 center dot 3, and 0 center dot 9 per 100 000 person-years in females worldwide. The incidence rates of adenocarcinoma exceeded those of squamous cell carcinoma in 150 of 185 countries in males and in all 185 countries in females. The highest age-standardised incidence rates per 100 000 person-years for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, for males occurred in eastern Asia (23 center dot 5), central and eastern Europe (17 center dot 5), western Asia (7 center dot 2), and south-eastern Asia (11 center dot 0); and for females occurred in eastern Asia (16 center dot 0), northern America (5 center dot 4), northern America (4 center dot 7), and south-eastern Asia (3 center dot 4). The incidence of each subtype showed a clear gradient according to the Human Development Index for male and female individuals, with increased rates in high and very high Human Development Index countries. Interpretation Adenocarcinoma has become the most common subtype of lung cancer globally in 2020, with incidence rates in males exceeding those of squamous cell carcinoma in most countries, and in females in all countries. Our findings provide new insights into the nature of the global lung cancer burden and facilitates tailored national preventive actions within each world region.Copyright (c) 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved.
Cite this article as: [1]Zhang Yanting, Vaccarella Salvatore, Morgan Eileen, et al.Global variations in lung cancer incidence by histological subtype in 2020: a population-based study[J].LANCET ONCOLOGY,2023,24(11):1206-1218.
微小RNA-96通过调控AMPKα2-FTO-m6A/MYC轴促进结直肠癌发生发展
Issue JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2020, Volume 39 Issue 1
期刊：《实验与临床癌症研究杂志》2020年，第39卷第1期
Author Yue Caifeng / Chen Jierong / Li Ziyue / Li Laisheng / Chen Jugao / Guo Yunmiao
Keywords Colorectal cancer / microRNA-96 / m6A modification / AMPKα / 2 / FTO / MYC
Abstract
Background Colorectal cancer (CRC) is one of the frequently occurred malignancies in the world. To date, several onco-microRNAs (miRNAs or miRs), including miR-96, have been identified in the pathogenesis of CRC. In the present study, we aimed to corroborate the oncogenic effect of miR-96 on CRC and to identify the specific mechanisms related to AMPK alpha 2/FTO/m6A/MYC. Methods RT-qPCR and Western blot analysis were performed to examine the expression pattern of miR-96, AMPK alpha 2, FTO and MYC in the clinical CRC tissues and cells. The relationship between miR-96 and AMPK alpha 2 was then predicted using in silico analysis and identified by dual-luciferase reporter assay. Gain- or loss-of-function approaches were manipulated to evaluate the modulatory effects of miR-96, AMPK alpha 2, FTO and MYC on cell growth, cycle progression and apoptosis. The mechanism of FTO-mediated m6A modification of MYC was analyzed via Me-RIP and PAR-CLIP analysis. The mediatory effects of miR-96 antagomir on cancerogenesis were validated in vivo. Results miR-96, FTO and MYC were upregulated, while AMPK alpha 2 was downregulated in CRC tissues and cells. miR-96 could down-regulate AMPK alpha 2, which led to increased expression of FTO and subsequent upregulated expression of MYC via blocking its m6A modification. This mechanism was involved in the pro-proliferative and anti-apoptotic roles of miR-96 in CRC cells. Besides, down-regulation of miR-96 exerted inhibitory effect on tumor growth in vivo. Conclusions Taken together, miR-96 antagomir could potentially retard the cancerogenesis in CRC via AMPK alpha 2-dependent inhibition of FTO and blocking FTO-mediated m6A modification of MYC, highlighting novel mechanisms associated with colorectal cancerogenesis.
Cite this article as: [1]Yue Caifeng, Chen Jierong, Li Ziyue, et al.microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis[J].JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2020,39(1).
piRNAs: biogenesis and their potential roles in cancer
PIWI相互作用RNA（piRNAs）：生物发生及其在癌症中的潜在作用
Issue CANCER AND METASTASIS REVIEWS 2020, Volume 39 Issue 2 564-575
期刊：《癌症与转移综述》2020年，第39卷第2期，第564-575页
Author Guo Binghong / Li Dongpei / Du Likun / Zhu Xiao
Keywords piRNAs / PIWI / Cancer metastasis / Biogenesis / piRISC
Abstract
With the length of about 26-31 nt, PIWI-interacting RNA (piRNA) is a small non-coding RNA (ncRNA) that interacts with PIWI proteins to form the piRNA silencing complex (piRISC). PIWI is a subfamily of Argonaute, and piRNA must bind to PIWI to exert its regulatory role. Current studies indicated that piRNA and PIWI are significantly abnormally expressed in gastric, breast, kidney, colon, and lung cancers, and are involved in the initiation, progression, and metastasis of cancers, which may be the potential diagnostic tools, prognostic markers, and therapeutic targets for cancers. By reviewing piRNA recent studies, this research summarized the mechanism of piRNA generation and the functions of piRNA/PIWI in gastric, breast, kidney, colon, and lung cancers, providing a reference value for further piRNA research.
Cite this article as: [1]Guo Binghong, Li Dongpei, Du Likun, et al.piRNAs: biogenesis and their potential roles in cancer[J].CANCER AND METASTASIS REVIEWS,2020,39(2):564-575.
Ⅲ期 ORIENT-11研究中，信迪利单抗联合培美曲塞与铂类药物作为局部晚期或转移性非鳞状非小细胞肺癌一线治疗方案的最新总生存期数据及预测性生物标志物
Issue JOURNAL OF THORACIC ONCOLOGY 2021, Volume 16 Issue 12 2109-2120
期刊：《胸部肿瘤学杂志》2021年，第16卷第12期，2109-2120页
Author Yang Yunpeng / Sun Jiya / Wang Zhehai / Fang Jian / Yu Qitao / Han Baohui / Cang Shundong / Chen Gongyan / Mei Xiaodong / Yang Zhixiong / Ma Rui / Bi Minghong / Ren Xiubao / Zhou Jianying / Li Baolan / Song Yong / Feng Jifeng / Li Juan / He Zhiyong / Zhou Rui / Li Weimin / Lu You / Zhou Hui / Wang Shuyan / Sun Luyao / Puig Oscar / Mancao Christoph / Peng Bo / Fang Wenfeng / Xu Wei / Zhang Li
Keywords Nonsquamous NSCLC / Sintilimab / RNA sequencing / MHC class-II antigen presentation pathway / Predictive biomarker
Abstract
Introduction: Sintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 study. Updated overall survival (OS) and PFS data and corresponding biomarker analyses are reported here. Methods: In this study, a total of 397 patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC were assigned to sintilimab plus chemotherapy combination treatment (combo) group or placebo plus chemotherapy treatment group. The patients were stratified by programmed death-ligand 1 (PD-L1) expression levels. Immune signature profiles from tumor RNA sequencing and PD-L1 immunohistochemistry were correlated with clinical outcome to identify predictive biomarkers. Results: As of January 2021, with median follow-up of 22.9 months, median OS was significantly improved in the combo group compared with the placebo plus chemotherapy treatment group (not reached versus 16.8 mo; hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.45-0.79, p = 0.0003). High or medium immune cell infiltration was strongly associated with improved PFS in the combo group, in contrast to absent or low immune cell infiltration, which suggests that chemotherapy could not prime "immune deserts" to obtain benefit from programmed cell death protein-1 inhibition. In particular, high major histocompatibility complex (MHC) class II presentation pathway expression was significantly correlated with prolonged PFS (HR = 0.32, 95% CI: 0.19-0.54, p < 0.0001) and OS (HR = 0.36, 95% CI: 0.20-0.64, p = 0.0005) in the combo group. Importantly, patients with low or absent PD L1 but high MHC class II expression could still benefit from the combo treatment. In contrast, MHC class I antigen presentation pathway was less relevant in this combination setting. Conclusions: The addition of sintilimab to chemotherapy resulted to significantly longer OS in nonsquamous NSCLC. Expression of MHC class II antigen presentation pathway could identify patients benefiting most from this combination. (c) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Cite this article as: [1]Yang Yunpeng, Sun Jiya, Wang Zhehai, et al.Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study[J].JOURNAL OF THORACIC ONCOLOGY,2021,16(12):2109-2120.
食用鱼油高脂饮食通过诱导促肿瘤巨噬细胞产生活性氧，实现肥胖与乳腺肿瘤生长的解偶联
Issue CANCER RESEARCH 2020, Volume 80 Issue 12 2564-2574
期刊：《癌症研究》2020年，第80卷第12期，2564-2574页
Author Liu Lianliang / Jin Rong / Hao Jiaqing / Zeng Jun / Yin Di / Yi Yanmei / Zhu Mingming / Mandal Anita / Hua Yuan / Ng Chin K. / Egilmez Nejat K. / Sauter Edward R. / Li Bing
Keywords
Abstract
Obesity is associated with increased risk of many types of cancer and can be induced by various high-fat diets (HFD) from different fat sources. It remains unknown whether fatty acid composition in different HFD influences obesity-associated tumor development. Here we report that consumption of either a cocoa butter or fish oil HFD induced similar obesity in mouse models. While obesity induced by the cocoa butter HFD was associated with accelerated mammary tumor growth, consumption of the fish oil HFD uncoupled obesity from increased mammary tumor growth and exhibited a decrease in protumor macrophages. Compared with fatty acid (FA) components in both HFDs, n-3 FA rich in the fish oil HFD induced significant production of reactive oxygen species (ROS) and macrophage death. Moreover, A-FABP expression in the protumor macrophages facilitated intracellular transportation of n-3 FA and oxidation of mitochondrial FA. A-FABP deficiency diminished n-3 FA-mediated ROS production and macrophage death in vitro and in vivo. Together, our results demonstrate a novel mechanism by which n-3 FA induce ROS-mediated protumor macrophage death in an A-FABP-dependent manner. Significance: This study provides mechanistic insight into dietary supplementation with fish oil for breast cancer prevention and advances a new concept that not all HFDs leading to obesity are tumorigenic.
Cite this article as: [1]Liu Lianliang, Jin Rong, Hao Jiaqing, et al.Consumption of the Fish Oil High-Fat Diet Uncouples Obesity and Mammary Tumor Growth through Induction of Reactive Oxygen Species in Protumor Macrophages[J].CANCER RESEARCH,2020,80(12):2564-2574.
